14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DSGN vs ERAS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over Design Therapeutics, Inc. (DSGN) on higher Unified Composite conviction (37.5/100 SELL vs. 49.8/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while DSGN wins 2–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus ERAS at $14.95 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (2–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4); meanwhile ERAS is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs ERAS. Trailing 12-month operating profitability (DSGN 0.0% vs ERAS 0.0%) and valuation multiples (DSGN N/M vs ERAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DSGN vs ERAS Key Questions & Quantitative Answers
As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over Design Therapeutics, Inc. (DSGN) on higher Unified Composite conviction (37.5/100 SELL vs. 49.8/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while DSGN wins 2–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus ERAS at $14.95 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (2–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4); meanwhile ERAS is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DSGN and ERAS split Growth & Scale metrics: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ERAS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus N/A for ERAS. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERAS.
DSGN and ERAS trade at balanced relative valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus ERAS (-48.7% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, ERAS carries 89.2% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.